Revisiting the benefits of isovolemic hemodilution red cell exchange for sickle cell disease
Journal of Clinical Apheresis · 2023
DOI: 10.1002/jca.22054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Apheresis, 2023. Verfasst von Manasa S Reddy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Transfusion Medicine and Cellular Therapy, Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Hemodilution. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Isovolemic hemodilution red cell exchange (IHD‐RCE) is a modified form of the standard red cell exchange (STD‐RCE), intended to reduce red cell requirements in patients with sickle cell disease (SCD). This retrospective crossover analysis of nine patients aims to add to the limited existing literature on IHD‐RCE and address the equipoise regarding whether the benefits of (a) decreased RBC usage per exchange and (b) increased interprocedure interval (via lower fraction of cells remaining, FCR) can be observed at the same time, in the same patient.
Methods
At a single center, we identified 37 patients with SCD undergoing chronic RCE between 2014 and 2021. We excluded those patients who did not have at least six consecutive procedures of each type (STD‐ and IHD‐RCE), arriving at nine patients for analysis.
Results
When using greater decreases in hematocrit than previously published, we did not find that IHD‐RCE resulted in any clinically apparent adverse events. We did find greater decreases in diastolic blood pressure and increases in heart rate in some patients, as compared to STD‐RCE. After correcting for total blood volume, seven of the nine patients had significantly reduced red cell requirements with each IHD‐RCE. Because the pattern of achieving a lower FCR than programmed was seen to an equal extent with both IHD‐RCE and STD‐RCE, none of the nine patients showed any statistical difference in actual FCR between procedure types.
Discussion
Our data do not support the observation of both IHD‐RCE benefits, decreased red cell usage per exchange and lower FCR/increased interprocedure interval, simultaneously.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Transfusion Medicine and Cellular Therapy, Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Indiana University Health Physicians, Indianapolis, Indiana, USA.
ORCID-Profile: Manasa S Reddy, Ahmad Alkashash
Zitieren
APA
Reddy, M. S., Alkashash, A., Nord, A., & Tetrick, A. (2023). Revisiting the benefits of isovolemic hemodilution red cell exchange for sickle cell disease. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.22054
Vancouver
Reddy MS, Alkashash A, Nord A, Tetrick A. Revisiting the benefits of isovolemic hemodilution red cell exchange for sickle cell disease. Journal of Clinical Apheresis. 2023. doi:10.1002/jca.22054
BibTeX
@article{Reddy2023,
author = {Reddy, Manasa S and Alkashash, Ahmad and Nord, Andrew and Tetrick, Anne},
title = {Revisiting the benefits of isovolemic hemodilution red cell exchange for sickle cell disease},
journal = {Journal of Clinical Apheresis},
year = {2023},
doi = {10.1002/jca.22054}
}
EUVIMED